9 Connections Between Menopause and Autoimmune Blood Disorders That Hematologists Rarely Discuss With Women
Getting a hematology referral in your forties and hearing nothing about perimenopause is one of those medical experiences that leaves women feeling like two separate bodies are being treated instead of one whole person. The hormonal context isn't a footnote here — for many women, it's the entire story. You deserve a workup that sees the full picture.
Learn more about Rose →Estrogen Actively Modulates the Immune System — and Its Withdrawal Destabilizes It
Estrogen receptors are expressed on virtually every immune cell type, including B cells, T cells, natural killer cells, and dendritic cells. When estrogen levels fluctuate and ultimately fall during perimenopause, the regulatory signals that kept immune tolerance in check are disrupted, creating conditions where the immune system is more likely to misidentify the body's own cells — including blood components — as threats. This isn't speculation; the female predominance of nearly all autoimmune diseases, and the well-documented peak of new diagnoses in midlife women, reflects this biology directly.
Immune Thrombocytopenia (ITP) Has a Documented Spike in Midlife Women
Immune thrombocytopenia — a condition where the immune system destroys platelets — shows a bimodal incidence pattern in women, with one peak in young adulthood and a second, less-discussed peak around the menopausal transition. In ITP, autoantibodies (typically IgG) coat platelets, flagging them for destruction by the spleen. The timing of this second peak aligns closely with perimenopause, yet hormonal status is rarely documented in hematology case notes or factored into treatment planning.
A Low Platelet Count Can Be Mistaken for Perimenopause Bleeding — and Vice Versa
Heavy, prolonged, or unpredictable menstrual bleeding is one of the most common symptoms of perimenopause, and it is also a hallmark sign of thrombocytopenia. When a woman reports flooding periods or bruising easily in her mid-forties, the default assumption is hormonal — which means a platelet disorder can go undiagnosed for months or even years. A simple full blood count with platelet measurement should arguably be standard in any perimenopause workup that includes abnormal uterine bleeding.
Antiphospholipid Syndrome Is Strongly Estrogen-Linked and Often Emerges in Midlife
Antiphospholipid syndrome (APS) — characterised by abnormal blood clotting and the presence of antiphospholipid antibodies — occurs predominantly in women and has well-established links to estrogen signalling. Estrogen appears to upregulate beta-2 glycoprotein I expression on cell membranes, which is the primary autoantigen in APS, potentially explaining why hormonal shifts can unmask or amplify the condition. New-onset unexplained clots, recurrent miscarriage history, or livedo reticularis appearing in the menopausal transition warrant antiphospholipid antibody testing with hormonal context noted.
Regulatory T Cells — the Immune System's Peacekeepers — Decline With Estrogen
Regulatory T cells (Tregs) suppress immune responses against the body's own tissues, and estrogen is one of their key supporters: it promotes Treg differentiation and function via estrogen receptor alpha signalling. As estrogen falls in perimenopause, Treg activity diminishes, and the threshold for autoreactive responses against blood cells, coagulation factors, and vascular endothelium effectively drops. This mechanistic pathway helps explain why several autoimmune blood disorders that were subclinical for years can become clinically significant during the menopausal transition.
Autoimmune Hemolytic Anemia Can Present — or Worsen — During Perimenopause
Autoimmune hemolytic anemia (AIHA), where the immune system produces antibodies against red blood cells, is significantly more common in women than men and tends to cluster in the fourth and fifth decades of life. Fatigue, pallor, and shortness of breath from AIHA are symptoms that overlap almost perfectly with common perimenopause complaints, meaning the anemia can be attributed to hormonal fatigue and missed entirely. Women presenting with unexplained anemia alongside classic perimenopausal symptoms should have a direct antiglobulin (Coombs) test included in their bloodwork.
Menopausal Hormone Therapy Adds Complexity — But Isn't Automatically Contraindicated
For women with newly diagnosed autoimmune blood disorders during perimenopause, the question of whether to use menopausal hormone therapy (MHT) is genuinely nuanced and requires specialist input. Estrogen-containing MHT carries an increased venous thromboembolism risk that is particularly relevant in APS, where clotting risk is already elevated — transdermal estrogen is generally considered lower risk than oral in this context because it avoids first-pass hepatic effects on coagulation. For ITP or AIHA, the picture is less clear-cut, and the potential immune-modulating effects of MHT remain an active area of research rather than settled clinical guidance.
The Inflammatory Shift of Menopause Creates a Fertile Ground for Autoimmunity
Menopause is associated with a measurable increase in systemic low-grade inflammation — sometimes called inflammaging — characterised by elevated levels of IL-6, TNF-alpha, and C-reactive protein. This pro-inflammatory environment lowers the threshold for autoimmune activation generally, and in the context of blood disorders, it amplifies the likelihood that autoreactive B cells will produce pathogenic antibodies against platelets, red cells, or phospholipid-binding proteins. Chronic inflammation and autoimmune blood disease are not independent findings in a midlife woman — they may be two expressions of the same underlying hormonal shift.
Hormonal Context Should Be Standard in Hematology Referral Letters — and It Rarely Is
When a GP or gynaecologist refers a perimenopausal woman to a hematologist, the referral letter seldom includes menstrual cycle changes, estimated menopausal stage, or current MHT use — information that could meaningfully change the diagnostic and treatment approach. Women can advocate for themselves by specifically asking their referring clinician to document hormonal context, and by proactively sharing this information with their hematologist even if they are not asked. The estrogen-immune axis is not a soft, lifestyle consideration — it is hard physiology, and it belongs in the workup.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.